Back in January this year, French company Withings, previously owned by Nokia and known as Nokia Health, announced one of the most interesting wrist gadgets in a while. The Withings ScanWatch is a combination of well-known Withings Steel HR and Withings Move ECG, we had on review.
The ScanWatch is capable of ECG measurement, SpO2 level measurement, continues heart rate tracking, all of which allows for sleep apnea detection and irregular sinus rhythm detection. It’s also a smart (hybrid) watch, meaning you can connect it to your phone for notifications. It is water-resistant to 50m and can track different physical activities.
Withings initially estimated that the ScanWatch will be launched during Q2 (April-June) 2020, after all the studies and approvals for the watch were received from different regulators. Because of COVID, the schedule was pushed back.
In a post on their official website, Withings CEO Mathieu Letombe announced that the ScanWatch will finally hit the market in September 2020, with limited availability during summer. Two out of three studies that tested Withings’ claims were finalized confirming “that ScanWatch is able to detect atrial fibrillation via ECG recording or via an optical sensor (PPG)” and “that ScanWatch is able to deliver a medical-grade SpO2 measurement”. The third study for sleep apnea is resumed and we should expect the results soon.
ScanWatch received the CE Medical certification which means it is ready for the European market and, as the CEO mentions in the post, “ScanWatch will be fully available in Europe on withings.com and on all trusted retail partner channels in September 2020 following the return to our normal production capacities.”
As a Steel HR Sport owner, I really like what the French company is doing and I am excited for the ScanWatch as well. The announced price of the ScanWatch starts at 249 euro for the 38mm version and 299 euro for 42mm version. We hope our review unit will soon arrive. 🙂